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Native ﬂuorescenceAbstract Simple, rapid and sensitive spectroscopic methods were developed and validated for the
determination of antiviral agents, namely, penciclovir (PCV) and entecavir (ETV). The ﬁrst method
is based on measuring the native ﬂuorescence of each of the cited drugs at its optimum excitation
and emission wavelengths. The ﬂuorescence intensity was measured for PCV & ETV at 363 nm and
370 nm upon excitation at 260 nm and 254 nm, respectively. The calibration curves were linear over
the concentration range 0.1–0.8, 0.025–0.4 lg ml1 for PCV and ETV, respectively. The second
method is based on measuring the amplitude of ETV in the fourth derivative with Dk= 8 and scal-
ing factor = 100 at 256.4 nm at which its acidic degradation showed zero reading over the concen-
tration range 5–60 lg ml1. The proposed methods were applied for the determination of the cited
drugs in bulk and pharmaceutical preparations. ICH guidelines were used for method validation.
 2016 Publishing services provided by Elsevier B.V. on behalf of Faculty of Pharmacy, Cairo University.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).1. Introduction
Penciclovir (PCV), [2-amino-9-[4-hydroxy-3-(hydroxymethyl)
butyl]-6,9-dihydro-3H-purin-6-one] and entecavir (ETV),
[2-Amino-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-meth
ylidenecyclopentyl]-6,9-dihydro-3H-purin-6-one] are antiviral
drugs, Fig. 1.1–3 PCV and ETV are nucleoside analogs, more
speciﬁcally guanosine analogs, that inhibit reverse transcrip-tion, DNA replication and transcription in the viral replica-
tion process by inhibiting DNA polymerase.4,5
A detailed survey of analytical literature of PCV revealed
several methods based on various techniques, HPLC using
UV6,7 ﬂuorescence8–11 and mass spectrometry12,13 as detectors
and capillary zone electrophoresis.14 Besides, different analyt-
ical methods for the determination of ETV have been reported,
including UV-spectrophotometry,15,16 HPLC using UV17–19
and mass spectrometry20–24 as detectors, and capillary zone
electrophoresis.25
Accordingly, the literature revealed that there is no
reported spectroﬂuorimetric method for the determination of
Figure 1 Chemical structures of (a) penciclovir, (b) entecavir.
Figure 2 The ﬂuorescence emission spectra of (A) Penciclovir at
concentrations of 0.1, 0.15, 0.4, and 0.5 lg ml1 and (B) Entecavir
at concentrations of 0.025, 0.05, 0.1, and 0.2 lg ml1.
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represents a direct method for the determination of the two
drugs. Moreover, no spectrophotometric method has been
reported for the determination of ETV in the presence of its
acidic degradation. Thus, the development of these spectro-
scopic methods for the determination of the cited drugs in bulk
and pharmaceutical preparations were of interest. Moreover,
the device used for the determination is available in each QC
laboratory.
2. Experimental
2.1. Instrumentation
A Shimadzu RF-1501 spectroﬂuorimetric (Kyoto-Japan). A
Crest ultrasonic processor model 575DAE (USA). Electronic
balance model HR200 (USA). UV Shimadzu UV/Visible
recording spectrophotometer 1601 (Japan) connected to an
IBM compatible computer and supported with UV probe soft-
ware version 2.2.1.
2.2. Reagents and reference samples
Pharmaceutical grade PCV (certiﬁed to contain 99.00%) and
penciclovir cream, nominally containing 10 mg of PCV per
g (batch No. 12042) were supplied by Sabaa Company, Egypt.
ETV (certiﬁed to contain 99.90%) and Hepaclude tablets,
nominally containing 1 mg of ETV per tablet (batch No.
120953A) were supplied by Chemipharm Company, Egypt.
Sulfuric acid analytical grade was supplied by Sigma–Aldrich
Laborchemikalien GmbH, Germany and distilled water was
supplied by ADWIC B.N.13100025, Egypt.
2.3. Standard and test solutions
2.3.1. Preparation of standard solutions
2.3.1.1. For spectrofluorimetric method. Standard stock solu-
tions of 2.5 lg ml1 of PCV and 1 lg ml1of ETV were pre-
pared in 0.1 M H2SO4.
2.3.1.2. For derivative method. Standard stock solution of
200 lg ml1 of ETV was prepared in distilled water.
2.3.2. Preparation of test solutions
2.3.2.1. For spectrofluorimetric method.
2.3.2.1.1. For penciclovir cream. Penciclovir cream (0.50 g)
was weighed and quantitatively transferred to a 100 ml volu-
metric ﬂask, then dissolved and completed to volume with0.1 M H2SO4. The solution was sonicated for 5 min then ﬁl-
tered through a ﬁlter paper. First 5 ml was rejected then an ali-
quot of the ﬁltrate was diluted using 0.1 M H2SO4 to obtain a
test solution of concentration of 2.5 lg ml1.
2.3.2.1.2. For Hepaclude tablets. Ten tablets were accu-
rately weighed and a quantity equivalent to 2 mg ETV was
transferred to a 100 ml volumetric ﬂask. Twenty ml of 0.1 M
H2SO4 was added and the solution was sonicated for 15 min
then completed to volume using the same solvent. The solution
was ﬁltered through ﬁlter paper to obtain a test solution of
concentration 20 lg ml1..Further dilution was done using
0.1 M H2SO4 to obtain a ﬁnal concentration of 1 lg ml
1.
2.3.2.2. For derivative method. Ten Hepaclude tablets were
accurately weighed and a quantity equivalent to 5 mg entecavir
was transferred to a 25 ml volumetric ﬂask. Ten ml distilled
water was added and the solution was sonicated for 15 min
then completed to volume using the same solvent and the solu-
tion was ﬁltered to obtain a test solution of concentration
200 lg ml1.
2.3.3. Preparation of acidic ETV degradation stock solution
Entecavir (100 mg) was reﬂuxed in 25 ml 5 N HCl for 72 h at
70 C. An aliquot (1 ml) of this solution was neutralized using
5 N NaOH then completed to 100 ml in a volumetric ﬂask with
distilled water to prepare acidic ETV degradation stock solu-
tion containing degradation equivalent to 40 lg ml1 of ETV.
2.4. General procedures and calibrations
2.4.1. For spectrofluorimetric method
Accurately measured aliquots of working standard solutions
equivalent to 0.1–0.8 and 0.025–0.4 lg ml1 of PCV and
ETV respectively were separately transferred into two sets of
10 ml volumetric ﬂasks; then each ﬂask was completed to vol-
ume with 0.1 M H2SO4. The native ﬂuorescence intensity (F)
was measured and used to plot a curve against concentration
(C), and the regression parameters were computed for each
drug.
2.4.2. For derivative method
Accurately measured aliquots of working standard solutions
equivalent to 5–60 lg ml1 ETV were separately transferred
into 10 ml volumetric ﬂasks; then each ﬂask was completed
to volume with distilled water. The amplitude after the deriva-
tization (A) with Dk= 8 and scaling factor = 100 at 256.4 nm
at which its acidic degradation showed zero reading, was mea-
sured and used to plot a curve against concentration (C), and
the regression parameters were computed.
Figure 3 Fourth derivative spectra show the calibration curve of
Entecavir (5, 10, 20, 30, 40, 60 lg ml1).
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3.1. Method development
3.1.1. For spectrofluorimetric method
Selection of excitation wavelengths of PCV and ETV was
based on the maximum wavelength of absorption in UV
region. Optimum excitation wavelengths found for PCV and
ETV were 260 nm and 254 nm, respectively. Also, selection
of suitable emission wavelength was done by scanning theFigure 4 Fourth derivative spectra show Entecavir (10 lg ml1) atemission spectra and measuring the variation in emission
intensity wavelength at a ﬁxed excitation wavelength. Opti-
mum emission wavelengths were found to be 363 nm,
370 nm, at their selected excitation wavelengths for PCV and
ETV, respectively. The ﬂuorescence emission spectra of PCV
and ETV are shown in Fig. 2. Sulfuric acid was found to be
more suitable than water as solvent with lowest background
noise at the selected excitation and emission wavelengths for
PCV and ETV while water shows no emission with the selected
drugs. Moreover, sulfuric acid gives satisfactory results along
with the experimental results.
3.1.2. For derivative method
The absorption spectrum of each solution of the calibration
curve was recorded (Fig. 3).The fourth derivative of the repre-
sented spectra of ETV standard and ETV acidic degradation
products were plotted with Dk= 8 and scaling factor = 100
at 256.4 nm at which its degradation showed zero reading
(Fig. 4).
3.2. Method validation
3.2.1. Linearity
Linearity was studied for the two cited drugs PCV and ETV.
In this study, 6 concentrations for each drug were used. A lin-
ear relationship between the ﬂuorescence intensity or the
amplitude and the component concentration (C) was obtained.
Range of linearity and regression equation: y= bc± a for
each drug is mentioned in Table 1. The linearity of the calibra-
tion curves was validated by the high values of correlation
coefﬁcients. The analytical data of the calibration curves
including standard deviations for the slope and intercept and
other characteristics are summarized in Table 1.
3.2.2. Accuracy
Accuracy of the results was checked by calculating % recovery
of six different concentrations of PCV and ETV and also by
applying the standard addition technique to the pharmaceuti-
cal preparations, all carried out in triplicate. The resultszero-reading of the acidic degradation (80 lg ml1) at 256.4 nm.
Table 1 Validation data of the analysis of PCV and ETV using the proposed spectroﬂuorimetric method.
Item Penciclovir Entecavir
kex 260 nm 254 nm
kem 363 nm 370 nm
LOD (lg ml1)* 0.01 0.01
LOQ (lg ml1)* 0.02 0.02
Range of linearity (lg ml1) 0.10–0.80 0.025–0.40
Regression equation Y= 911.95x+ 140.48 Y= 2085.87x+ 129.60
Correlation coeﬃcient (r) 0.99 0.99
Sb
** 4.93 6.70
Sa
** 2.42 29.82
Standard error of estimation 2.96 9.91
Intraday (RSD%) 0.03–0.07 0.07–0.14
Inter-day (RSD%) 0.62–1.05 0.52–0.82
Drug in bulk % 99.77 ± 0.60 100.16 ± 0.83
Drug labeled % 100.00 ± 0.66 98.09 ± 0.08
Drug added % 99.56 ± 0.44 100.79 ± 0.91
* LOD= 3.3 SD/S, LOQ= 10 SD/S.
** Sb is the standard deviation of slope, Sa the standard deviation of intercept.
Table 2 Validation data of analysis of ETV using the
proposed derivative spectrophotometric method.
Item Derivative method of ETV
k of measurements 256.4 nm
LOD (lg ml1)* 0.50
LOQ (lg ml1)* 1.52
Range of linearity (lg ml1) 5.00–60.00
Regression equation Y= 0.004x+ 0.003
Correlation coeﬃcient (r) 0.99
Sb
** 0.06 * 103
Sa
** 0.22 * 102
Standard error of estimation 0.03 * 101
Intraday (RSD%) 0.59–0.78
Inter-day (RSD%) 0.58–0.87
Drug in bulk % 100.08 ± 0.49
Drug labeled % 98.68 ± 0.47
Drug added % 99.50 ± 0.47
* LOD= 3.3SD/S, LOQ= 10SD/S.
** Sb is the standard deviation of slope, Sa the standard deviation
of intercept.
Table 3 Statistical comparison between the recovery results of the
drugs. (N= 6).*
ETV
Reference method** Fluorimetric method Spectrometr
Mean 100.70 100.16 100.08
SD 0.73 0.83 0.49
t-value**** 1.52 2.01
F ratio***** 1.29 2.19
* N is the number of samples for reference method and F ratio.
** The reference method of the manufacturer. (Sabaa Company, HPLC
*** The reference method of the manufacturer. (Chemipharma Company
**** The t-tabulated value (2.23).
***** F ratio (5.05).
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deviation, and relative standard deviation, are displayed in
Tables 1 and 2.
3.2.3. Precision
Precision was estimated by repeatability which was assessed by
analyzing a solution of 30 lg ml1 and 0.1 lg ml1 of ETV
(n= 6) for derivative spectrophotometric method & spec-
troﬂuorimetric method, respectively, and a solution of
0.5 lg ml1 of PCV for the spectroﬂuorimetric method. The
values of the precision (% R.S.D) of repeatability along with
intraday and inter-day precision (using 3 different concentra-
tions in triplicate for three consecutive days) for the two drugs
are displayed in Tables 1 and 2.
3.2.4. Specificity
Speciﬁcity is the ability of the analytical method to identify the
analyte response in the presence of any interference. In the pre-
sent work, the spectra of the samples of the dosage form were
checked for the appearance of any new spectra of the excipi-
ents. No interference from any of the excipients was found
at the excitation/emission wavelengths of the examined drugs
and in the fourth derivative spectroscopic method. In addition,proposed spectroscopic and the reference methods for the cited
PCV
ic derivative method Reference method*** Fluorimetric method
99.62 99.77
0.66 0.60
0.41
0.83
-UV detection at 254 nm.
, HPLC-UV detection at 254 nm).
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that received by the standard solution at the wavelengths
applied. Besides, good recoveries were obtained for the sam-
ples. Moreover, the derivative spectrophotometric method
was able to determine ETV without any interference from its
acidic degradation product.
3.2.5. Limit of detection and limit of quantification
Limit of detection (LOD) which represents the concentration
of analyte at SD/S ratio of 3.3 and limit of quantiﬁcation
(LOQ) at which SD/S is 10, were determined for the proposed
method, and results are given in Table 1.
3.3. Statistical analysis
A statistical analysis of the results obtained by the proposed
spectroscopic methods for the determination of PCV and
ETV and those obtained by the manufacturer reported meth-
ods was carried out by ‘‘SPSS statistical package version
11”, as shown in Table 3. The test ascertained that there was
no signiﬁcant difference between the proposed method and
the reference methods reported by the manufacturer by using
the independent t-value (2.23) at P< 0.05 (Table 3).
4. Conclusion
The proposed spectroscopic methods have the advantage of
simplicity, precision, accuracy, and convenience for the deter-
mination of the cited antiviral drugs: penciclovir and entecavir.
Hence, the proposed methods can be used for the routine qual-
ity control of the cited drugs in bulk and in pharmaceutical
preparations in laboratories.
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